THE ATTEMPTS OF MIKHAIL BLAGOSKLONNY TO CURE AGING

Through technology, innovation and massive research, scientists have been able to make great discoveries. These have led to solutions of some of the worst nightmares that the world has seen and more challenges are yet to be solved. One of these is aging. Everyone wants to look and stay young and this has driven many people to undertake expensive remedies but at the end of the day, aging still catches up with people. This topic of aging has driven Mikhail Blagosklonny a renown oncologist to dedicate a substantial amount of his research to its study.

In his recent hypothesis, he proposes that Target Of Rapamycin (TOR) could be responsible for aging in organisms. He argues that TOR; a substance responsible for regulating the usage of substances such as amino acids, insulin and growth factors in the body results in over-stimulation of body cells making them fail to function adequately. As a result the various organs wear out thus causing aging. He recommends the use of rapamycin; a cancer drug in the treatment of aging. Read more about Mikhail at LinkedIn

Other interests of Blagosklonny include research on cancer, cell cycle, mitosis and molecular and cellular biology. He loves sharing his knowledge and has published over 250 peer reviewed articles. To further support spread of scientific knowledge, he co-founded Oncotarget. This is a weekly medical journal that publishes papers on various biomedical fields. It has a team of editors who review the papers to ensure that they are up to standard and credible. He is also an editor of other journals such Cancer Research, Cell Death and Differentiation and Autography.

Mikhail Blagosklonny has a strong education background in biomedical sciences. He was a student at First Pavlov States Medical University of St. Peterburg degree in internal medicine and a PhD in experimental medicine and cardiology. He currently works as a professor of oncology at Roswell Park Cancer Institute. At the institute he works on developing new methods of cancer prevention and treatment in an attempt to offer more options to cancer patients. He also has an extensive work experience having worked at the New York Medical College and the Ordway Research Institute in New York. Visit ResearchGate to know more about Mikhail’s latest work.

An Overview of Oncotarget Peer-Reviewed Medical Journal

Oncotarget refers to a multidisciplinary journal with free access; it publishes various papers on a weekly basis. The journal has a mission of ensuring that scientific results are available widely and rapidly. It also aims to ensure that exceptional discoveries are shared quickly. Oncotarget aims at eliminating the borders that exist between specialties and provide links to the different biomedical science fields. It is under the leadership of prominent scientists who aim at helping various researchers to contribute to progress in science.

Impact Factor and Rank

Oncotarget ranks among the top medical journals in terms of the total documents published in Oncology. It is the highest ranking medical journal in the field of oncology. In the year 2015/2016, the journal had an impact factor (IF) of 5.008 and a total of 10452 cites. The medical journal was launched in 2010 and has managed to publish over 370 papers on topics related to oxygen.

Oncotarget Editors

At Oncotarget, there is an existing editorial board and two editors-in-chief. The two are Andrei V. Gudkov and Mikhail V, Blagosklonny. Andrei V. Gudkov, PhD., DSci, Professor is based at Roswell Park Cancer Institute as the senior vice president. He has degrees in molecular biology and experimental oncology from Russia (Moscow State University and National Cancer Institute respectively). His areas of research on dovepress.com interests include gene discovery, drug discovery and molecular targets necessary for cancer treatment.

Mikhail V. Blagosklonny, M.D., PhD., Professor, is also based at the Roswell Park Cancer Institute, Buffalo, NY. He is an author of more than 200 articles that have been published in peer-reviewed journals on bioxbio. He is an associate editor of Cell Death Differ, Cancer Res, Autophagy, Cancer Biol Ther, Am J pathology, Int J Cancer, PLOS ONE and the Cell Cycle editor-in-chief. His research interest areas include molecular and cellular biology, clinical investigations, cell cycle, signal transduction, anticancer therapeutics and cellular senescence. He is emphasizing on translating basic science into new strategies to fight cancer. In the recent past, Dr. Blagosklonny has extended his studies to signal transduction pathways from cancer and turned his focus on aging. This has revealed some potential targets on impactjournals.com for slowing down age-related diseases and aging.

E-cigarettes causing damage to gum tissues

According to a study published on Oncotarget, there are suggestions that electronic cigarettes are causing damages to the gum tissues. The study was conducted at UR School of Medicine and Dentistry, led by a professor of Environmental Medicine, Irfan Rahmann, Ph.D. It is the first scientific study on e-cigarettes causing detrimental effects on oral health on molecular and cellular levels.